Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients

Vista sencilla de ítem
dc.contributor.authorMuñoz-Vendrell, Albert
dc.contributor.authorCampoy, Sergio
dc.contributor.authorCaronna, Edoardo
dc.contributor.authorAlpuente Ruiz, Alicia
dc.contributor.authorTorres Ferrús, Marta
dc.contributor.authorNieves Castellanos, Candela
dc.contributor.authorOlivier, M.
dc.contributor.authorCampdelacreu Fumadó, Jaume
dc.contributor.authorPrat, Joan
dc.contributor.authorCamiña Muñiz, J.
dc.contributor.authorMolina Martínez, Francisco José
dc.contributor.authorMínguez Olaondo, Ane
dc.contributor.authorRuibal, M.
dc.contributor.authorSantos Lasaosa, Sonia
dc.contributor.authorNavarro Pérez, María Pilar
dc.contributor.authorMorollón, Noemí
dc.contributor.authorLópez Bravo, Alba
dc.contributor.authorCano Sánchez, L.M.
dc.contributor.authorGarcía-Sánchez, S.M.
dc.contributor.authorGarcía-Ull, Jesica
dc.contributor.authorRubio-Flores, Laura.
dc.contributor.authorGonzalez Martinez, Alicia
dc.contributor.authorQuintas, Sonia
dc.contributor.authorEchavarría Íñiguez, Ana
dc.contributor.authorGil Luque, Sendoa
dc.contributor.authorCastro-Sánchez, M.V.
dc.contributor.authorAdell Ortega, V.
dc.contributor.authorGarcía Alhama, J.
dc.contributor.authorBerrocal-Izquierdo, N.
dc.contributor.authorBelvís Nieto, Roberto
dc.contributor.authorDíaz Insa, Samuel
dc.contributor.authorPozo Rosich, Patricia
dc.contributor.authorHuerta Villanueva, Mariano
dc.date.accessioned2025-06-18T15:09:05Z
dc.date.available2025-06-18T15:09:05Z
dc.date.issued2023-06-02
dc.date.updated2025-06-18T15:09:04Z
dc.description.abstractBackground: Anti-CGRP monoclonal antibodies have shown notable effectiveness and tolerability in migraine patients; however, data on their use in elderly patients is still lacking, as clinical trials have implicit age restrictions and real-world evidence is scarce. In this study, we aimed to describe the safety and effectiveness of erenumab, galcanezumab and fremanezumab in migraine patients over 65 years old in real-life. Methods: In this observational real-life study, a retrospective analysis of prospectively collected data from 18 different headache units in Spain was performed. Migraine patients who started treatment with any anti-CGRP monoclonal antibody after the age of 65 years were included. Primary endpoints were reduction in monthly migraine days after 6 months of treatment and the presence of adverse effects. Secondary endpoints were reductions in headache and medication intake frequencies by months 3 and 6, response rates, changes in patient-reported outcomes and reasons for discontinuation. As a subanalysis, reduction in monthly migraine days and proportion of adverse effects were also compared among the three monoclonal antibodies. Results: A total of 162 patients were included, median age 68 years (range 65–87), 74.1% women. 42% had dyslipidaemia, 40.3% hypertension, 8% diabetes, and 6.2% previous cardiovascular ischaemic disease. The reduction in monthly migraine days at month 6 was 10.1 ± 7.3 days. A total of 25.3% of patients presented adverse effects, all of them mild, with only two cases of blood pressure increase. Headache and medication intake frequencies were significantly reduced, and patient-reported outcomes were improved. The proportions of responders were 68%, 57%, 33% and 9% for reductions in monthly migraine days ≥ 30%, ≥ 50%, ≥ 75% and 100%, respectively. A total of 72.8% of patients continued with the treatment after 6 months. The reduction in migraine days was similar for the different anti-CGRP treatments, but fewer adverse effects were detected with fremanezumab (7.7%). Conclusions: Anti-CGRP mAbs are safe and effective treatments in migraine patients over 65 years old in real-life clinical practice. Graphical Abstract: [Figure not available: see fulltext.]en
dc.identifier.citationMuñoz-Vendrell, A., Campoy, S., Caronna, E., Alpuente, A., Torres-Ferrus, M., Nieves Castellanos, C., Olivier, M., Campdelacreu, J., Prat, J., Camiña Muñiz, J., Molina Martínez, F. J., Mínguez-Olaondo, A., Ruibal Salgado, M., Santos Lasaosa, S., Navarro Pérez, M. P., Morollón, N., López Bravo, A., Cano Sánchez, L. M., García-Sánchez, S. M., et al. (2023). Effectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patients. Journal of Headache and Pain, 24(1). https://doi.org/10.1186/S10194-023-01585-2
dc.identifier.doi10.1186/S10194-023-01585-2
dc.identifier.eissn1129-2377
dc.identifier.issn1129-2369
dc.identifier.urihttps://hdl.handle.net/20.500.14454/3090
dc.language.isoeng
dc.publisherBioMed Central Ltd
dc.rights© The Author(s) 2023
dc.subject.other65 years old
dc.subject.otherCalcitonin gene-related peptide
dc.subject.otherMigraine
dc.subject.otherMonoclonal antibodies
dc.subject.otherReal-world
dc.titleEffectiveness and safety of anti-CGRP monoclonal antibodies in patients over 65 years: a real-life multicentre analysis of 162 patientsen
dc.typejournal article
dcterms.accessRightsopen access
oaire.citation.issue1
oaire.citation.titleJournal of Headache and Pain
oaire.citation.volume24
oaire.licenseConditionhttps://creativecommons.org/licenses/by/4.0/
oaire.versionVoR
Archivos
Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
munoz_effectiveness_2023.pdf
Tamaño:
1.64 MB
Formato:
Adobe Portable Document Format
Descargar
Colecciones
Artículos